» Articles » PMID: 25759844

HIV and the Gut Microbiota, Partners in Crime: Breaking the Vicious Cycle to Unearth New Therapeutic Targets

Overview
Journal J Immunol Res
Publisher Wiley
Date 2015 Mar 12
PMID 25759844
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The gut microbiota plays a key role in health and immune system education and surveillance. The delicate balance between microbial growth and containment is controlled by the immune system. However, this balance is disrupted in cases of chronic viral infections such as HIV. This virus is capable of drastically altering the immune system and gastrointestinal environment leading to significant changes to the gut microbiota and mucosal permeability resulting in microbial translocation from the gut into the peripheral blood. The changes made locally in the gut have far-reaching consequences on the other organs of the body starting in the liver, where microbes and their products are normally filtered out, and extending to the blood and even brain. Microbial translocation and their downstream effects such as increased indolamine 2,3-dioxygenase (IDO) enzyme expression and activity create a self-sustaining feedback loop which enhances HIV disease progression and constitute a vicious cycle of inflammation and immune activation combining viral and bacterial factors. Understanding this self-perpetuating cycle could be a key element in developing new therapies aimed at the gut microbiota and its fallout after infection.

Citing Articles

Intestinal Microbiota and Aging in People with HIV-What We Know and What We Don't.

Islam S, Singh S, Keshavarzian A, Abdel-Mohsen M Curr HIV/AIDS Rep. 2024; 22(1):9.

PMID: 39666149 PMC: 11874070. DOI: 10.1007/s11904-024-00717-w.


Nuclear Factor Kappa B p65: A Possible Biomarker for Persistent Inflammation in HIV-1 Infection?.

Gnanaskandan S, Srikanth P Cureus. 2024; 16(10):e71308.

PMID: 39529759 PMC: 11552464. DOI: 10.7759/cureus.71308.


Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas.

Papantoniou E, Arvanitakis K, Markakis K, Papadakos S, Tsachouridou O, Popovic D Life (Basel). 2024; 14(4).

PMID: 38672720 PMC: 11051320. DOI: 10.3390/life14040449.


Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.

Mehraj V, Chen J, Routy J Front Immunol. 2024; 15:1339338.

PMID: 38655259 PMC: 11035727. DOI: 10.3389/fimmu.2024.1339338.


Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging.

Singh S, Giron L, Shaikh M, Shankaran S, Engen P, Bogin Z Microbiome. 2024; 12(1):31.

PMID: 38383483 PMC: 10882811. DOI: 10.1186/s40168-024-01758-4.


References
1.
Corona A, Norden D, Skendelas J, Huang Y, OConnor J, Lawson M . Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav Immun. 2012; 31:134-42. PMC: 3554840. DOI: 10.1016/j.bbi.2012.08.008. View

2.
Assimakopoulos S, Dimitropoulou D, Marangos M, Gogos C . Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies. Infection. 2014; 42(6):951-9. DOI: 10.1007/s15010-014-0666-5. View

3.
Moffett J, Namboodiri M . Tryptophan and the immune response. Immunol Cell Biol. 2003; 81(4):247-65. DOI: 10.1046/j.1440-1711.2003.t01-1-01177.x. View

4.
Planes R, Bahraoui E . HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. PLoS One. 2013; 8(9):e74551. PMC: 3779232. DOI: 10.1371/journal.pone.0074551. View

5.
Cunningham-Rundles S, Ahrne S, Johann-Liang R, Abuav R, Dunn-Navarra A, Grassey C . Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection. Nutrients. 2012; 3(12):1042-70. PMC: 3260491. DOI: 10.3390/nu3121042. View